Immune Gene Therapy of Cancer

Overview

Journal Turk J Med Sci

Specialty General Medicine

Date 2020 Jun 10

PMID 32512674

Citations 6

Authors

Hakan Akbulut

Affiliations

Soon will be listed here.

Abstract

Cancer gene therapy emerged as a promising treatment modality 3 decades ago. However, the failure of the first gene therapy trials in cancer treatment has decreased its popularity. Likewise, immunotherapy has followed a similar course. While it was a popular and promising treatment with IL-2 and interferon and cancer vaccines in the 1980s, it later lost its popularity. Immunotherapy became one of the main options for cancer treatment with the successful use of immune checkpoint inhibitors in clinics approximately 10 years ago. The success of immunotherapy has increased even more with the introduction of cancer gene therapy methods in this area. With the identification of the oncolytic herpes simplex virus and Chimeric antigen receptor (CAR) T-cells, immune gene therapy has become an essential modality in cancer treatments such as surgery, radiotherapy, chemotherapy, and targeted therapies.

Citing Articles

Advancements in nanomedicine delivery systems: unraveling immune regulation strategies for tumor immunotherapy.

Zhang Y, Chen X, Hu B, Zou B, Xu Y Nanomedicine (Lond). 2024; 19(21-22):1821-1840.

PMID: 39011582 PMC: 11418288. DOI: 10.1080/17435889.2024.2374230.

Mechanism of action of nadofaragene firadenovec-vncg.

Narayan V, Meeks J, Jakobsen J, Shore N, Sant G, Konety B Front Oncol. 2024; 14:1359725.

PMID: 38559556 PMC: 10979480. DOI: 10.3389/fonc.2024.1359725.

Recent advances of engineered oncolytic viruses-based combination therapy for liver cancer.

Zhang J, Xiao Y, Zhang J, Yang Y, Zhang L, Liang F J Transl Med. 2024; 22(1):3.

PMID: 38167076 PMC: 10763442. DOI: 10.1186/s12967-023-04817-w.

-Mediated Herpes Simplex Virus-TK/Ganciclovir Treatment Inhibits Cancer Metastasis in Mouse Model.

Wang C, Shen Y, Ma Y Int J Mol Sci. 2023; 24(14).

PMID: 37511481 PMC: 10380465. DOI: 10.3390/ijms241411721.

Analysis of the regulatory mechanisms of prognostic immune factors in thyroid cancer.

Tian Y, Xie T, Sun X Front Oncol. 2023; 12:1059591.

PMID: 36591507 PMC: 9795211. DOI: 10.3389/fonc.2022.1059591.

References

Grigg C, Blake Z, Gartrell R, Sacher A, Taback B, Saenger Y . Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers. Semin Oncol. 2017; 43(6):638-646. DOI: 10.1053/j.seminoncol.2016.10.005. View

Akbulut H, Coleri A, SahIn G, Tang Y, Icli F . A Bicistronic Adenoviral Vector Carrying Cytosine Deaminase and Granulocyte-Macrophage Colony-Stimulating Factor Increases the Therapeutic Efficacy of Cancer Gene Therapy. Hum Gene Ther. 2019; 30(8):999-1007. DOI: 10.1089/hum.2018.245. View

Mackiewicz J, Karczewska-Dzionk A, Laciak M, Kapcinska M, Wiznerowicz M, Burzykowski T . Whole Cell Therapeutic Vaccine Modified With Hyper-IL6 for Combinational Treatment of Nonresected Advanced Melanoma. Medicine (Baltimore). 2015; 94(21):e853. PMC: 4616404. DOI: 10.1097/MD.0000000000000853. View

Gore M, Griffin C, Hancock B, Patel P, Pyle L, Aitchison M . Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet. 2010; 375(9715):641-8. PMC: 2835851. DOI: 10.1016/S0140-6736(09)61921-8. View

Ito Z, Kan S, Bito T, Horiuchi S, Akasu T, Yoshida S . Predicted Markers of Overall Survival in Pancreatic Cancer Patients Receiving Dendritic Cell Vaccinations Targeting WT1. Oncology. 2019; 97(3):135-148. DOI: 10.1159/000500359. View

Lambricht L, Lopes A, Kos S, Sersa G, Preat V, Vandermeulen G . Clinical potential of electroporation for gene therapy and DNA vaccine delivery. Expert Opin Drug Deliv. 2015; 13(2):295-310. DOI: 10.1517/17425247.2016.1121990. View

Martinez M, Moon E . CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. Front Immunol. 2019; 10:128. PMC: 6370640. DOI: 10.3389/fimmu.2019.00128. View

Leoni V, Vannini A, Gatta V, Rambaldi J, Sanapo M, Barboni C . A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors. PLoS Pathog. 2018; 14(8):e1007209. PMC: 6095629. DOI: 10.1371/journal.ppat.1007209. View

Hwang K, Cho W, Yoo J, Yun H, Kim S, Im D . Adenovirus-mediated interleukin-12 gene transfer combined with cytosine deaminase followed by 5-fluorocytosine treatment exerts potent antitumor activity in Renca tumor-bearing mice. BMC Cancer. 2005; 5:51. PMC: 1168891. DOI: 10.1186/1471-2407-5-51. View

10.

Candolfi M, Curtin J, Xiong W, Kroeger K, Liu C, Rentsendorj A . Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells. Mol Ther. 2006; 14(3):371-81. PMC: 1629029. DOI: 10.1016/j.ymthe.2006.05.006. View

11.

Wierda W, Castro J, Aguillon R, Sampath D, Jalayer A, McMannis J . A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154. Leukemia. 2010; 24(11):1893-900. PMC: 4556366. DOI: 10.1038/leu.2010.191. View

12.

Nemunaitis J, Jahan T, Ross H, Sterman D, Richards D, Fox B . Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther. 2006; 13(6):555-62. DOI: 10.1038/sj.cgt.7700922. View

13.

Darvin P, Toor S, Sasidharan Nair V, Elkord E . Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018; 50(12):1-11. PMC: 6292890. DOI: 10.1038/s12276-018-0191-1. View

14.

Baldin A, Savvateeva L, Bazhin A, Zamyatnin Jr A . Dendritic Cells in Anticancer Vaccination: Rationale for Ex Vivo Loading or In Vivo Targeting. Cancers (Basel). 2020; 12(3). PMC: 7139354. DOI: 10.3390/cancers12030590. View

15.

Di Lorenzo G, Buonerba C, Kantoff P . Immunotherapy for the treatment of prostate cancer. Nat Rev Clin Oncol. 2011; 8(9):551-61. DOI: 10.1038/nrclinonc.2011.72. View

16.

Deisseroth A, Tang Y, Zhang L, Akbulut H, Habib N . TAA/ecdCD40L adenoviral prime-protein boost vaccine for cancer and infectious diseases. Cancer Gene Ther. 2012; 20(2):65-9. DOI: 10.1038/cgt.2012.87. View

17.

Lee J, Lee M, Garon E, Goldman J, Salehi-Rad R, Baratelli F . Phase I Trial of Intratumoral Injection of Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8 T-cell Infiltration. Clin Cancer Res. 2017; 23(16):4556-4568. PMC: 5599263. DOI: 10.1158/1078-0432.CCR-16-2821. View

18.

de la Cruz-Lopez K, Castro-Munoz L, Reyes-Hernandez D, Garcia-Carranca A, Manzo-Merino J . Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches. Front Oncol. 2019; 9:1143. PMC: 6839026. DOI: 10.3389/fonc.2019.01143. View

19.

Mackiewicz A, Mackiewicz J, Wysocki P, Wiznerowicz M, Kapcinska M, Laciak M . Long-term survival of high-risk melanoma patients immunized with a Hyper-IL-6-modified allogeneic whole-cell vaccine after complete resection. Expert Opin Investig Drugs. 2012; 21(6):773-83. DOI: 10.1517/13543784.2012.684753. View

20.

Vargas J, Chicaybam L, Stein R, Tanuri A, Delgado-Canedo A, Bonamino M . Retroviral vectors and transposons for stable gene therapy: advances, current challenges and perspectives. J Transl Med. 2016; 14(1):288. PMC: 5059932. DOI: 10.1186/s12967-016-1047-x. View